Transcranial Magnetic Stimulation System Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Deep Transcranial Magnetic Stimulation, Repetitive Transcranial Magnetic Stimulation, Others), By Application (Alzheimer’s Disease, Depression, Parkinson’s Disease, Epilepsy, Others), By Age Group (Adults, Children), By Region and Competition, 2020-2030F

Market Overview

The Global Transcranial Magnetic Stimulation System Market, valued at USD 1.65 Billion in 2024, is projected to experience a CAGR of 6.93% to reach USD 2.47 Billion by 2030. Transcranial Magnetic Stimulation (TMS) systems are non-invasive medical devices that utilize magnetic fields to induce electrical currents in targeted brain regions for therapeutic modulation of neural activity. The global market for these systems is primarily driven by the escalating prevalence of neurological and psychiatric disorders, coupled with increasing awareness of non-invasive treatment options. Furthermore, continuous technological advancements, enhancing device efficacy and precision, actively support market expansion. According to the World Health Organization data published in February 2024, approximately 50 million individuals globally live with epilepsy, highlighting a significant patient population for potential TMS applications.

A notable challenge impeding the market's growth remains the high initial cost associated with TMS devices and treatments. This financial barrier can limit adoption, particularly in regions with developing healthcare infrastructure or less comprehensive reimbursement policies. Additionally, the requirement for adequately trained professionals to operate these specialized systems presents an operational hurdle.

Key Market Drivers

The escalating prevalence of neurological and mental health conditions profoundly influences the global Transcranial Magnetic Stimulation System market by expanding the fundamental patient population requiring advanced therapeutic interventions. Widespread conditions like major depressive disorder, anxiety disorders, and obsessive-compulsive disorder necessitate effective treatment modalities beyond conventional pharmacotherapy. This growing disease burden directly translates into increased demand for non-invasive options such as TMS, particularly for individuals not adequately responding to medication or seeking alternative approaches. The sheer scale of these challenges underscores the urgent need for accessible and efficacious treatments. According to the World Health Organization, in September 2025, over one billion people globally are living with mental health disorders, significantly driving the imperative for innovative neurostimulation technologies to address this extensive patient demographic.

Technological advancements in TMS systems are concurrently propelling market expansion by enhancing treatment efficacy, precision, and patient convenience. Innovations in coil design enable deeper and more targeted brain stimulation, while refined treatment protocols improve therapeutic outcomes and broaden clinical utility. These advancements address previous limitations, making TMS a more compelling option for both practitioners and patients. A notable development includes, according to BrainsWay Ltd.,in September 2025, the U.S. Food and Drug Administration granted an expanded clearance for its Deep Transcranial Magnetic Stimulation system to include an accelerated protocol for major depressive disorder, shortening the acute treatment phase to just six days. This progress streamlines treatment delivery and lowers patient burden, fostering greater adoption. Furthermore, the overall market activity reflects this positive trajectory; Neuronetics Inc. reported, in June 2024, its NeuroStar Advanced Therapy had delivered over 6.4 million treatments for major depressive disorder in adults, demonstrating substantial patient reach and growing acceptance of TMS as a viable therapeutic solution.

Download Free Sample Report

Key Market Challenges

The high initial cost associated with Transcranial Magnetic Stimulation (TMS) devices and treatments represents a significant barrier to market expansion. Healthcare providers, particularly those in regions with developing healthcare infrastructure or constrained budgets, face considerable challenges in allocating capital for such advanced equipment. This financial impediment directly restricts the broad adoption of TMS technology, limiting its availability to a wider patient demographic and hindering market penetration. The cost factor extends beyond the purchase price to include installation, specialized facility modifications, and ongoing maintenance expenses.

This substantial investment requirement results in cautious procurement by healthcare institutions, which must balance the benefits of innovative therapies with immediate budgetary priorities. According to the Advanced Medical Technology Association (AdvaMed) in 2023, there was a significant tightening in overall industry financing for medical technology, including a 21% drop in venture capital funding. Such a conservative investment climate, exacerbated by high equipment costs, directly curtails the widespread deployment of TMS systems and consequently impedes overall market growth.

Key Market Trends

The global Transcranial Magnetic Stimulation System market is significantly influenced by the development of specialized clinical infrastructure and continuous technological enhancements. Two prominent and distinct trends driving market evolution are the rise of specialized outpatient TMS clinics and the increasing adoption of navigated TMS systems. These trends address both accessibility and precision in patient care, fostering broader acceptance and utilization of TMS therapy.

The rise of specialized outpatient TMS clinics represents a critical trend, expanding access to advanced neurostimulation treatments beyond traditional hospital settings. These dedicated facilities streamline patient pathways, offering focused expertise and environments conducive to long-term care for conditions like major depressive disorder and obsessive-compulsive disorder. The expansion of these clinics is often driven by manufacturers, with companies actively supporting the establishment of new treatment centers. For instance, BrainsWay Ltd. reported a significant expansion on the U.S. East Coast through an order for 14 new Deep TMS systems in September 2024, bringing its installed base to 1,215 Deep TMS systems as of June 30, 2024. This growth in dedicated clinical sites reflects a strategic effort to make TMS therapy more accessible to a wider patient demographic.

Concurrently, the increasing adoption of navigated TMS systems marks a substantial advancement in treatment precision and efficacy. Navigated TMS integrates imaging and tracking technologies to precisely target specific brain regions, thereby enhancing therapeutic outcomes and minimizing off-target stimulation. This technological evolution allows clinicians to customize treatment delivery based on individual patient neuroanatomy, moving towards more personalized and effective interventions. A notable development in this area includes Magstim receiving FDA clearance for its Horizon 3.0 with StimGuide Pro in November 2024, which is recognized as the first integrated TMS system with navigation capabilities designed for precise treatment targeting. This advancement underscores the industry's commitment to refining TMS technology, improving both the safety and effectiveness of treatments for patients.

Segmental Insights

Repetitive Transcranial Magnetic Stimulation (rTMS) stands out as the fastest-growing segment within the Global Transcranial Magnetic Stimulation System Market. This rapid expansion is primarily driven by the increasing demand for non-invasive, drug-free therapeutic options for various neuropsychiatric conditions, particularly treatment-resistant depression. The segment's growth is further propelled by strong clinical validation demonstrating its effectiveness in alleviating symptoms, as well as supportive regulatory approvals from bodies such as the U.S. Food and Drug Administration (FDA) for multiple indications. Enhanced patient awareness regarding alternative mental health treatments, coupled with expanding insurance coverage, also significantly contributes to the rising adoption of rTMS therapies.

Regional Insights

North America holds the leading position in the global Transcranial Magnetic Stimulation system market, primarily driven by its well-established healthcare infrastructure and significant investments in research and development. The region experiences a high prevalence of neurological and psychiatric disorders, including major depressive disorder and obsessive-compulsive disorder, which consistently fuels the demand for advanced non-invasive treatment options. Furthermore, favorable reimbursement policies from institutions such as the Centers for Medicare and Medicaid Services, coupled with crucial regulatory clearances by the U. S. Food and Drug Administration for various TMS indications, have significantly propelled market expansion and fostered widespread adoption among both healthcare providers and patients.

Recent Developments

• In October 2025, Zeta Surgical announced that its AI-powered Zeta TMS Navigation System obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). This innovative device offers image-guided, real-time coil positioning for transcranial magnetic stimulation procedures. The system integrates advanced 3D imaging with motion-aware tracking technology, ensuring precise target alignment even with patient movement. This FDA clearance covers the use of the Zeta TMS Navigation System as a stereotaxic image-guidance system for accurate placement of TMS treatment coils to specific brain targets, intending to enhance treatment efficacy in clinical environments.

• In September 2025, BrainsWay announced it had received FDA clearance for an accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol designed for the treatment of Major Depressive Disorder (MDD), including cases with comorbid anxiety symptoms. This new protocol substantially reduces the acute treatment phase from the standard four weeks to just six days. The clearance was based on results from a multicenter clinical study, which demonstrated that the accelerated protocol achieved comparable efficacy to the traditional approach in reducing depression symptoms and maintaining high response and remission rates. This breakthrough aims to enhance patient convenience and accessibility to Deep TMS therapy.

• In August 2025, MagVenture received U.S. Food and Drug Administration (FDA) clearance to expand the indication for its MagVenture TMS Therapy® system. The system can now be used as an adjunctive treatment for Major Depressive Disorder (MDD) in adolescents and young adults aged 15 to 21 who have not adequately responded to antidepressant medications. This expansion broadens safe and effective treatment options for a younger patient population, addressing a significant unmet need in mental healthcare. Additionally, MagVenture secured FDA clearance for its new T65 coil, designed to improve patient comfort and streamline clinical workflows by integrating previous coil features into a single, more ergonomic device.

• In May 2024, Neuronetics partnered with Humana to broaden access to NeuroStar transcranial magnetic stimulation (TMS) therapy for adolescents grappling with major depressive disorder (MDD). Humana became the first commercial insurance provider to update its policy following the FDA's recent clearance of NeuroStar TMS for individuals aged 15 to 21. This policy revision affects approximately 600,000 young individuals and mandates a medical director review for treatment requests concerning patients aged 15-17. This collaboration marks a significant step towards providing effective, non-pharmacological interventions for this underserved adolescent population.

Key Market Players

• BrainsWay Ltd.
• Magstim, Inc.
• Nexstim Oyj
• MagVenture A/S
• eNeura Inc.
• Koninklijke Philips N.V.
• Labtician Ophthalmics, Inc.
• Vision Care USA, Inc.

Report Scope:

In this report, the Global Transcranial Magnetic Stimulation System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Transcranial Magnetic Stimulation System Market, By Type:

o   Deep Transcranial Magnetic Stimulation

o   Repetitive Transcranial Magnetic Stimulation

o   Others

• Transcranial Magnetic Stimulation System Market, By Application:

o   Alzheimer’s Disease

o   Depression

o   Parkinson’s Disease

o   Epilepsy

o   Others

• Transcranial Magnetic Stimulation System Market, By Age Group:

o   Adults

o   Children

• Transcranial Magnetic Stimulation System Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Transcranial Magnetic Stimulation System Market.

Available Customizations:

Global Transcranial Magnetic Stimulation System Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Transcranial Magnetic Stimulation System Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]